April 3rd 2025
A new survey study will assess how well German memory clinics and specialists are equipped to provide early and accurate Alzheimer diagnoses using biomarker-based methods.
Get direct access to interviews with experts, as well as the latest data and clinical news updates, straight from the conference floor in Dallas, Texas.
Burst Expert Illustrations & Commentary™: Visualizing the Role of FcRN in Neurological Disorders
View More
BURST Expert Illustrations and Commentaries™: Visualizing FcRn as a Therapeutic Target in Neurological Disease
View More
BURST Expert Illustrations and Commentaries™: Visualizing the Implications of FcRN-Targeted Therapies on Generalized Myasthenia Gravis
View More
Clinical Consultations™: Navigating the Evolving Treatment Landscape in Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of Subcutaneous Infusion as an Alternate Administration Route for Medical Interventions
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
Alzheimer Biomarkers pTau217 and pTau181 Show High Group-Level Correlation With Trial End Points
Investigators at AD/PD 2025 presented new data showing that changes in plasma p-tau217 and p-tau181 closely correlate with clinical outcomes in anti-amyloid therapy trials for Alzheimer disease.
NeuroVoices: Cynthia Lemere, PhD, on Exploring the Role of Complement in ARIA and CAA
The professor of neurology at Brigham and Women’s Hospital gave clinical insights on the therapeutic potential of targeting compliment as a way to mitigate risk for amyloid-related imaging abnormalities from antiamyloid therapies.
Higher CSF Aß42/Total Tau Ratio Associated With Increased ARIA Risk in Lecanemab
Research suggests that CSF ATI ratios could serve as a biomarker for identifying patients with Alzheimer disease at higher risk of ARIA during lecanemab treatment, aiding in safer patient management.
Eli Lilly Announces Expanded Services to Early Diagnosis and Access Alzheimer Disease Care
Eli Lilly’s expanded LillyDirect platform tackles barriers in Alzheimer disease diagnosis and care, offering telehealth and in-person options through Healthgrades and Synapticure, with a focus on timely access and patient support.
Ubrogepant During Migraine Prodrome Shows Significant Benefits in Patient-Reported Outcomes
March 31st 2025A recent analysis of the PRODROME trial explored the impact of ubrogepant, an FDA-approved acute treatment of migraine with or without aura, on patient-reported outcomes in migraine management.
Mixed Bruxism Episodes More Common in Migraine and Temporomandibular Disorders, Study Finds
March 30th 2025A recent case-control study suggests that although sleep bruxism may not be directly associated with migraine in patients with temporomandibular disorders, mixed bruxism episodes occur more frequently in those with migraine.
WVE-N531 Improves Muscle Health in Latest Phase 2 Trial of Duchenne Muscular Dystrophy
WVE-N531, an investigational exon-skipping therapy, showed promising 48-week results in the FORWARD-53 study, marking the first-ever improvement in muscle health for patients with Duchenne muscular dystrophy, with plans for an NDA filing in 2026.
Breaking the Stigma: Improving Epilepsy Awareness and Care
Emma Macdonald-Laurs, PhD, FRACP, MBChB, a neurologist at the Royal Children’s Hospital in Melbourne, Australia, provided commentary on the progress and challenges the epilepsy community faces amid Purple Day.